This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 442 results found since Jan 2013.

Porous chitosan microspheres for application as quick in vitro and in vivo hemostat
We reported the fabrication of porous chitosan microspheres (CSMS) with tunable surface pore size by microemulsion combined with thermally induced phase separation technique, and its application as a quick hemostat. Their hemostatic property was characterized by blood clotting kinetics, adherence interaction between red blood cells/platelets and CSMS, in vitro and in vivo hemostasis by rat tail amputation and liver laceration models, and histological analysis. Their density, surface area, porosity, water absorption ratio were 0.04–0.06g/cm3, 28.2–31.5m2/g, 98%, and 15.5–23.2g/g, respectively. The surface pore was con...
Source: Materials Science and Engineering: C - April 4, 2017 Category: Materials Science Source Type: research

New Absorbable Adjunctive Hemostat From Ethicon Helps Surgeons Control Disruptive Bleeding More Efficiently
SURGICEL® Powder is the next innovation in bleeding management designed to help improve operating efficiency SOMERVILLE, N.J., Jan. 9, 2018 -- (Healthcare Sales & Marketing Network) -- Ethicon*, part of the Johnson & Johnson Medical Devices Compani... Devices, Surgery, Product Launch Ethicon, Johnson & Johnson, SURGICEL, ABSORBABLE HEMOSTAT, hemostat
Source: HSMN NewsFeed - January 9, 2018 Category: Pharmaceuticals Source Type: news

Convesaid, a Hemostat Powder Spray That Can ’t Cause Embolisms
Team Consulting, a firm based out of an old barn in Cambridge, UK that develops medical devices, one being the EpiPen, has now come up with a hemostat powder sprayer that cannot cause embolisms. When spraying a powder onto a leaking vein, the air tha...
Source: Medgadget - March 16, 2018 Category: Medical Devices Authors: Editors Tags: Cardiac Surgery Emergency Medicine Thoracic Surgery Vascular Surgery Source Type: blogs

Baxter closes $153m hemostat, sealant asset buy from Mallinckrodt
Baxter (NYSE:BAX) said today that it closed the $153 million acquisition of hemostat and sealant assets from Mallinckrodt Pharmaceuticals (NYSE:MNK). Baxter announced in January its plan to acquire the stand-alone recombinant thrombin Recothrom and Preveleak surgical sealant for vascular reconstruction. “We are excited to add both Recothrom and Preveleak to our portfolio of hemostats and sealants to offer surgeons additional options that address different situations when intraoperative bleeding can occur,” advanced surgery president Wil Boren said in prepared remarks. “Our top priority right now is wor...
Source: Mass Device - March 19, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Surgical Vascular Wall Street Beat Baxter Mallinckrodt Source Type: news

Gel-E wins FDA OTC nod for gel-e Flex flowable hemostat
Early stage wound care company Gel-e said today it won FDA 510(k) clearance for its gel-e Flex as an over-the-counter flowable hemostat. The College Park, Md.-based company said the clearance expands the labeling for the local management of lacerations and minor bleeding, and said the products were specifically designed to be usable by both trained professionals and patients. “This clearance is the next step in expanding our OTC product line, and will be a key component of gel-e’s 21st Century First Aid Kit. We are continuing to develop a tool kit that will provide the best possible options for all manner of...
Source: Mass Device - June 29, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Wound Care gel-e Source Type: news

An Injectable Hemostat Composed of a Polyphosphate-Conjugated Hyaluronan Hydrogel.
Abstract We have developed a new hydrogel hemostat composed of hyaluronan (HA) conjugated with inorganic polyphosphate (PolyP). A hemostatic hydrogel, HAX-PolyP, was formed rapidly by mixing aldehyde-modified HA and hydrazide-modified HA conjugated with PolyP (HA-PolyP). Although the gelation rate decreased with increasing PolyP content, the gelation time was below 5 min. In addition, the hydrogel swelling volume decreased with increasing PolyP content, but the degradation rate did not depend on PolyP content and the hydrogel underwent complete degradation through hydrolysis over 3 weeks in phosphate buffered sali...
Source: Biomacromolecules - July 9, 2018 Category: Biochemistry Authors: Sakoda M, Kaneko M, Ohta S, Qi P, Ichimura S, Yatomi Y, Ito T Tags: Biomacromolecules Source Type: research

Effects of Ankaferd Hemostat on red blood cell aggregation: a hemorheological study
Conclusion: ABS has antierythroid aggregation effect. ABS inhibits pathological aggregation of red blood cells. Antithrombotic clinical effects of ABS may be ascribed to the antierythroid aggregan actions of the drug. PMID: 30761848 [PubMed - in process]
Source: Turkish Journal of Medical Sciences - February 16, 2019 Category: General Medicine Tags: Turk J Med Sci Source Type: research

Ankaferd hemostat: from molecules to medicine.
ANKAFERD HEMOSTAT: FROM MOLECULES TO MEDICINE. Turk J Med Sci. 2020 Apr 14;: Authors: Çiftçiler R, Haznedaroglu IC Abstract Ankaferd hemostat (ABS; Ankaferd blood stopper®, Istanbul, Turkey) is a hemostatic agent having an impact on red blood cell-fibrinogen interactions. The hemostatic effect of ABS depends upon the quick promotion of a protein network, particularly fibrinogen gamma, in relation to the erythrocyte aggregation. The entire physiological process involves ABS-induced formation of the protein network by vital erythrocyte aggregation. Vital erythroid aggregation occurs with the spectrine...
Source: Turkish Journal of Medical Sciences - April 15, 2020 Category: General Medicine Tags: Turk J Med Sci Source Type: research

Physico-mechanical and biological evaluation of an injectable m-TG cross-linked thrombin loaded amended gelatin hemostat to heal liver trauma
The objective of this study was to evaluate the activation of a coagulation system both in vitro and in vivo. We assessed detailed physical characteristics of a microbial transglutaminase (m-TG) crosslinked thrombin (TB) laden Gelatin (Gel) hemostat sealant in vitro and its hemostatic efficacy for controlling bleeding caused by liver trauma in rats as well as its efficacy for organ regeneration after making a critical defect. The prepared hemostat gel showed almost seven times higher absorbance behavior than a negative control. Thrombogenicity of the prepared gel was determined based on platelet adhesion, whole blood clott...
Source: International Journal of Biological Macromolecules - March 30, 2021 Category: Biochemistry Authors: Thanh Lan Chu Garima Tripathi Bae Sang Ho Byong-Taek Lee Source Type: research

Granular hemostat deposits mimicking disseminated malignancy
We present two cases that highlight the importance of full knowledge of product usage during previous operations and the need for histological examination of these lesions.
Source: Journal of Pediatric Surgery - March 1, 2013 Category: Surgery Authors: Sarah J. Wood, Anna Kelsey, Bernadette Brennan, James Bruce, Ross J. Craigie Tags: Journal of Pediatric Surgery Electronic Pages (Available only online at www.jpedsurg.org) Source Type: research

Chinese Starch Medicals Perclot Patent Claims Denied - Impact for Cryolife predicted
Recently denied claims for China based Perclot manufacturer Starch Medical have seen Starch re-file a dramatically reduced set of claims revised patent application published May 16, 2013 (see HERE). The original 2009 filing which includes "Inventors" Ji Xin (James Ji), previously Chinese Distributor of Medafor's Arista, has now dropped Jianping Chen (Jane Chen) as an "Inventor". Of more critical importance the patent has now shrunk in respect of claims made. Currently claims 1-53 have now been cancelled and it seems likely this patent is less than secure.The EU search indicates denial regarding incorrect cla...
Source: Medical Hemostat - May 22, 2013 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Cohera Medical Completes Enrollment of Sylys™ Surgical Sealant Clinical Trial
PITTSBURGH, May 30, 2013 -- /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, today announced the completion of enrollment of its clinical trial for Sylys, the first and only resorbable synthetic sealant specifically designed to significantly reduce anastomotic leakage in bowel procedures.Currently underway in Europe, the study is evaluating the safety of Sylys on the reduction of anastomotic leakage following bowel repair. The study included patients enrolled at two sites in the Netherlands."We are excited to conclude enrollment in this signi...
Source: Medical Hemostat - May 31, 2013 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs

Court Enters Order Under Which Vascular Solutions Will Cease Manufacture, Sales and Distribution of R-Band
SOMERSET, N.J., May 21, 2013 /PRNewswire/ -- Terumo Medical Corporation (Terumo), today announced that it was pleased with the U.S. District Court for the District of New Jersey's Order approving an agreement of the parties under which Vascular Solutions Inc. will cease further manufacture, sales, and distribution of its R-Band™ Radial Hemostasis Device, pending litigation of Terumo's claims.In February, Terumo filed a patent infringement lawsuit alleging that the R Band™ Radial Hemostasis Device infringes on U.S. patent and trademark rights held by Terumo Medical Corporation for its proprietary TR Band™ Radial Compr...
Source: Medical Hemostat - June 12, 2013 Category: Technology Consultants Authors: hemostatguy at gmail.com (hemostat guy) Source Type: blogs